Panacea Biotec has declared the launch of generic version of anti-platelet medication Prasugrel 5mg and 10mg  tablets in US.

Panacea’s Prasugrel copies are first to file abbreviated new drug applications (ANDAs) to be approved by USFDA.

Canada based Apotex, Panacea’s partner will be disturbing and marketing the drug in US.

Prasugrel, the equivalent of the generic version of Eli Lilly’s Effient, is used to prevent heart attacks.

As per Rajesh Jain, Joint Managing Director of Panacea, “Approval and launch of this first-to-file ANDA product is an important milestone to achieve growth in our US business.”

Read EquityPandit’s Technical Analysis on Nifty Pharma